Search research articles
Contact Us
Filters
Showing results (101-110 of 115) with videos related to
Page
of 12
Sort By:
Genes, Chromosomes & Cancer
|
July 15, 2005
Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia
David A Sweetser, Andrew J Peniket, Christina Haaland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2012
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
Muling Mao, Feng Tian, John M Mariadason, et al.
JCO Precision Oncology
|
December 8, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
Brandon M Huffman, Vasily N Aushev, Griffin L Budde, et al.
Journal for Immunotherapy of Cancer
|
January 22, 2026
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer
Dung T Le, Gunnar Folprecht, Anna M Varghese, et al.
Nature Medicine
|
June 23, 2022
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
Andrew X Zhu, Alexander R Abbas, Marina Ruiz de Galarreta, et al.
Cancer Letters
|
June 10, 2026
The germline MLH1 c.2054 C>T mutation disrupts DNA mismatch repair and is detectable by digital PCR
Matthew R Moldenhauer, Aditya Mahadevan, Cameron Hom, et al.
The Oncologist
|
April 12, 2026
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315)
Adel Mandl, Ruizhe Chen, Satya Das, et al.
Journal for Immunotherapy of Cancer
|
October 17, 2022
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
Landon C Brown, Jason Zhu, Kunal Desai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Geoffrey Ku, Lin Shen, Farshid Dayyani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer
Thatcher Ross Heumann, Jiayun Lu, Hao Wang, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 115) with videos related to
Sort By:
Page
of 12
Genes, Chromosomes & Cancer
|
July 15, 2005
Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia
David A Sweetser, Andrew J Peniket, Christina Haaland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2012
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
Muling Mao, Feng Tian, John M Mariadason, et al.
JCO Precision Oncology
|
December 8, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
Brandon M Huffman, Vasily N Aushev, Griffin L Budde, et al.
Journal for Immunotherapy of Cancer
|
January 22, 2026
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer
Dung T Le, Gunnar Folprecht, Anna M Varghese, et al.
Nature Medicine
|
June 23, 2022
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
Andrew X Zhu, Alexander R Abbas, Marina Ruiz de Galarreta, et al.
Cancer Letters
|
June 10, 2026
The germline MLH1 c.2054 C>T mutation disrupts DNA mismatch repair and is detectable by digital PCR
Matthew R Moldenhauer, Aditya Mahadevan, Cameron Hom, et al.
The Oncologist
|
April 12, 2026
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315)
Adel Mandl, Ruizhe Chen, Satya Das, et al.
Journal for Immunotherapy of Cancer
|
October 17, 2022
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
Landon C Brown, Jason Zhu, Kunal Desai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Geoffrey Ku, Lin Shen, Farshid Dayyani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer
Thatcher Ross Heumann, Jiayun Lu, Hao Wang, et al.
Page
of 12